Home drugs Jakafi (Ruxolitinib Phosphate)

Jakafi (Ruxolitinib Phosphate)

This page contains brief information about ruxolitinib phosphate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)      Jakafi
FDA Approved            Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ruxolitinib phosphate is approved to treat:

  • Myelofibrosis (a bone marrow disease) that is intermediate or high-risk, including the following types:
    • Primary myelofibrosis.
    • Post-polycythemia vera myelofibrosis.
    • Post-essential thrombocythemia myelofibrosis.
  • Polycythemia vera in patients who cannot be treated with or have not gotten better with hydroxyurea.

Ruxolitinib phosphate is also being studied in the treatment of some types of cancer.

More About Ruxolitinib Phosphate

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ruxolitinib Phosphate – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials Accepting Patients

Find Clinical Trials for Ruxolitinib Phosphate – Check for trials from TCH’s list of cancer clinical trials now accepting patients.